Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines

Virology

Volumn 400, Issue 1, 2010, Pages 53-67

  Davies, Michael L ^a   Xu, Shushen ^a   Lyons Weiler, James ^b   Rosendorff, Adam ^c   Webber, Steven A ^c   Wasil, Laura R ^a   Metes, Diana ^d   Rowe, David T ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

B cell differentiation; B cells; Epstein Barr virus; Herpesvirus; Latency III; Lymphoblastoid cell lines; Lytic reactivation; Unfolded protein response

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD69 ANTIGEN; CELL PROTEIN; CELL SURFACE MARKER; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 3A; EPSTEIN BARR VIRUS ANTIGEN 3C; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; LATENT MEMBRANE PROTEIN 2B; LYTIC F PROMOTER; MESSENGER RNA; PROTEIN BMLF1; SYNDECAN 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; B LYMPHOCYTE; CELL LINEAGE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOLYSIS; DAUDI CELL; DNA CONTENT; EPSTEIN BARR VIRUS; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS GENE; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; ANTIGENS, CD; B-LYMPHOCYTES; BASE SEQUENCE; CELL LINE; CHILD; DNA PRIMERS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; PROMOTER REGIONS, GENETIC; VIRUS ACTIVATION; VIRUS LATENCY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 77649188072     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.01.002     Document Type: Article

References (88)

1. Adhikary D., Behrends U., Boerschamm H., Pfünder A., Burdach S., Moosmann A., Witter K., Bornkamm G.W., and Mautner J. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS ONE 2 7 (2007) e583
2. Adler B., Schaadt E., Kempkes B., Zimber-Strobl U., Baier B., and Bornkamm G.W. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 437-442
3. Alsaleh G., Suffert G., Semaan N., Juncker T., Frenzel L., Gottenberg J.-E., Sibilla J., Pfeffer S., and Wachsmann D. Bruton's tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J. Immunol. 182 8 (2009) 5088-5097
4. Babel N., Vergopoulos A., Trappe R.U., Oertel S., Hammer M.H., Kairavanov S., Schneider N., Reiss H., Papp-Vary M., Neuhaus R., Gondek L.P., Volk H.D., and Reinke P. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation 84 3 (2007) 387-391
5. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., and Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 6 (2003) 711-723
6. Bhende P.M., Dickerson S.J., Sun X., Feng W.-H., and Kenney S.C. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J. Virol. 81 14 (2007) 7363-7370
7. Bogunia-Kubik K., Mlynarczewska A., Jaskula E., and Lange A. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br. J. Haematol. 132 3 (2005) 326-332
8. Bollard C.M., Aguilar L., Straathof K.C., Gahn B., Huls M.H., Rousseau A., Sixbey J., Gresik M.V., Carrum G., Hudson M., Dilloo D., Gee A., Brenner M.K., Rooney C.M., and Hislop H.E. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J. Exp. Med. 200 12 (2004) 1623-1633
9. Browne E.P., Wing B., Coleman D., and Shenk T. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J. Virol. 75 24 (2001) 12319-12330
10. Cahir-McFarland E.D., Carter K., Rosenwald A., Giltnane J.M., Henrickson S.E., Staudt L.M., and Kieff E. Role of NF-{kappa}B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus Latency III-infected cells. J. Virol. 78 8 (2004) 4108-4119
11. Carter K.L., Cahir-McFarland E., and Kieff E. Epstein Barr virus-induced changes in B-lymphocyte gene expression. J. Virol. 76 20 (2002) 10427-10436
12. Chang Y., Lee H.-H., Chen Y.-Y., Lu J., Wu S.-Y., Chen C.-W., Takada K., and Tsai C.-H. Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. J. Virol. 80 15 (2006) 7748-7755
13. Chen A., Zhao B., Kieff E., Aster J.C., and Wang F. EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J. Virol. 80 20 (2006) 10139-10150
14. Countryman J.K., Gradoville L., and Miller G. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J. Virol. 82 10 (2008) 4706-4719
15. Croonquist P.A., Linden M.A., Zhao F., and Van Ness B.G. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood 102 7 (2003) 2581-2592
16. da Silva G.N., Bacchi M.M., Rainho C.A., and de Oliveira D.E. Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma. Arch. Pathol. Lab. Med. 131 11 (2007) 1691-1696
17. Dierksheide J.E., Baiocchi R.A., Ferketich A.K., Roychowdhury S., Pelletier R.P., Eisenbeis C.F., Caligiuri M.A., and VanBuskirk A.M. IFN-{gamma} gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood 105 4 (2005) 1558-1565
18. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun. Rev. 7 2 (2007) 96-101
19. Dolcetti R., Quaia M., Gloghini A., De Re V., Zancai P., Cariati R., Babuin L., Cilia A.M., Rizzo S., Carbone A., and Boiocchi M. Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease. Int. J. Cancer 80 2 (1999) 240-249
20. Durandy A., Le Deist F., Emile J.-F., Debatin K., and Fischer A. Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1/fas antibody. Eur. J. Immunol. 27 2 (1997) 538-543
21. Elliott J., Goodhew E.B., Krug L.T., Shakhnovsky N., Yoo L., and Speck S.H. Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines. J. Virol. 78 24 (2004) 14062-14065
22. Fukuda M., and Longnecker R. Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J. Virol. 79 13 (2005) 8655-8660
23. Gatto G., Rossi A., Rossi D., Kroening S., Bonatti S., and Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-{kappa}B pathway. Nucleic Acids Res. 36 20 (2008) 6608-6619
24. Gregory C.D., Dive C., Henderson S., Smith C.A., Williams G.T., Gordon J., and Rickinson A.B. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349 6310 (1991) 612-614
25. Haddad R., Guardiola P., Izac B., Thibault C., Radich J., Delezoide A.L., Baillou C., Lemoine F.M., Gluckman J.C., Pflumio F., and Canque B. Molecular characterization of early human T/NK and B-lymphoid progenitor cells in umbilical cord blood. Blood 104 13 (2004) 3918-3926
26. Hatta K., Morimoto A., Ishii E., Kimura H., Ueda I., Hibi S., Todo S., Sugimoto T., and Imashuku S. Association of transforming growth factor-{beta}1 gene polymorphism in the development of Epstein-Barr virus-related hematologic diseases. Haematologica 92 11 (2007) 1470-1474
27. Huang D.W., Sherman B.T., and Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 1 (2009) 44-57
28. Inga A., Storici F., Darden T.A., and Resnick M.A. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol. Cell. Biol. 22 24 (2002) 8612-8625
29. Jenkins F.J., Rowe D.T., and Rinaldo C.R. Herpesvirus infections in organ transplant recipients. Clin. Diagn. Lab. Immunol. 10 1 (2003) 1-7
30. John S.A., Clements J.L., Russell L.M., and Garrett-Sinha L.A. Ets-1 regulates plasma cell differentiation by interfering with the activity of the transcription factor Blimp-1. J. Biol. Chem. 283 2 (2008) 951-962
31. Keating S., Prince S., Jones M., and Rowe M. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J. Virol. 76 16 (2002) 8179-8188
32. Khanolkar A., Fu Z., Underwood L.J., Bondurant K.L., Rochford R., and Cannon M.J. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells. J. Immunol. 170 6 (2003) 3187-3194
33. Khodarev N.N., Advani S.J., Gupta N., Roizman B., and Weichselbaum R.R. Accumulation of specific RNAs encoding transcriptional factors and stress response proteins against a background of severe depletion of cellular RNAs in cells infected with herpes simplex virus 1. Proc. Natl. Acad. Sci. U. S. A. 96 21 (1999) 12062-12067
34. Kieff E., and Rickinson A.B. Epstein-Barr virus and its replication. In: Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5th ed. Vol. 2 (2007), Lippincott, Williams & Wilkins, Philadelphia 2603-2654 2 vols
35. Klein U., Gloghini A., Gaidano G., Chadburn A., Cesarman E., Dalla-Favera R., and Carbone A. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101 10 (2003) 4115-4121
36. Kluiver J., Haralambieva E., de Jong D., Blokzijl T., Jacobs S., Kroesen B.J., Poppema S., and van den Berg A. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer 45 2 (2006) 147-153
37. Kong W., Yang H., He L., Zhao J.-J., Coppola D., Dalton W.S., and Cheng J.Q. MicroRNA-155 is regulated by the transforming growth factor {beta}/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 28 22 (2008) 6773-6784
38. Kip1 in Marek's disease virus-transformed tumour cell line MSB-1. J. Gen. Virol. 90 5 (2009) 1164-1171
39. Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26 15 (2007) 3699-3708
40. Lee D.Y., and Sugden B. The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis. Blood 111 4 (2008) 2280-2289
41. Lee D.Y., Lee J., and Sugden B. The unfolded protein response and autophagy: herpesviruses rule!. J. Virol. 83 3 (2009) 1168-1172
42. Lu L.-F., Thai T.-H., Calado D.P., Chaudhry A., Kubo M., Tanaka K., Loeb G.B., Lee H., Yoshimura A., Rajewsky K., and Rudensky A.Y. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30 1 (2009) 80-91
43. Markasz L., Stuber G., Flaberg E., Jernberg Å., Eksborg S., Olah E., Skribek H., and Szekely L. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer 6 (2006) 265
44. Merluzzi S., Moretti M., Altamura S., Zwollo P., Sigvardsson M., Vitale G., and Pucillo C. CD40 stimulation induces Pax5/BSAP and EBF activity through an APE/Ref-1-dependent redox mechanism. J. Biol. Chem. 279 3 (2004) 1777-1786
45. Morris M.A., Dawson C.W., Wei W., O'Neil J.D., Stewart S.E., Jia J., Bell A.I., Young L.S., and Arrand J.R. Epstein-Barr virus-encoded LMP1 induces a hyperproliferative and inflammatory gene expression programme in cultured keratinocytes. J. Gen. Virol. 89 11 (2008) 2806-2820
46. Nakayama T., Fujisawa R., Izawa D., Hieshima K., Takada K., and Yoshie O. Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR10 and downregulate CXCR4 and CXCR5. J. Virol. 76 6 (2002) 3072-3077
47. Nakayama T., Hieshima K., Izawa D., Tatsumi Y., Kanamaru A., and Yoshie O. Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J. Immunol. 170 3 (2003) 1136-1140
48. Naranatt P.P., Krishnan H.H., Svojanovsky S.R., Bloomer C., Mathur S., and Chandran B. Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: Insights into modulation events early during infection. Cancer Res. 64 1 (2004) 72-84
49. Niens M., van den Ber A., Diepstra A., Nolte I.M., van der Steege G., Gallagher A., Taylor G.M., Jarrett R.F., Poppema S., and te Meerman G.J. The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol. Biomark. Prev. 15 11 (2006) 2280-2284
50. Nutt S.L., and Kee B.L. The transcription regulation of B cell lineage commitment. Immunity 26 6 (2007) 715-725
51. O'Connell R.M., Chaudhuri A.A., Rao D.S., and Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. U. S. A. 106 17 (2009) 7113-7118
52. Patel S., and Lyons-Weiler J. caGEDA: a web application for the integrated analysis of global gene expression patterns in cancer. Appl. Bioinformatics 3 1 (2004) 49-62
53. Portis T., and Longnecker R. Epstein-Barr virus (EBV) LMP2A interferes with global transcription factor regulation when expressed during B lymphocyte development. J. Virol. 77 1 (2003) 105-114
54. Rickinson A.B., and Kieff E. Epstein-Barr virus. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5th ed. Vol. 2 (2007), Lippincott, Williams & Wilkins, Philadelphia 2655-2700 2 vols
55. Rochford R., Hobbs M.V., Garnier J.-L., Cooper N.R., and Cannon M.J. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 352-356
56. Ryan J.L., Kaufmann W.K., Raab-Traub N., Oglesbee S.E., Carey L.A., and Gulley M.L. Clonal evolution of lymphoblastoid cell lines. Lab. Invest. 86 11 (2006) 1193-1200
57. Sana T.R., Janatpour M.J., Sathe M., McEvoy L.M., and McClanahan T.K. Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine 29 6 (2005) 256-269
58. Schaadt E., Baier B., Mautner J., Bornkamm G.W., and Adler B. Epstein-Barr virus latent membrane protein 2A mimics B-cell receptor-dependent virus reactivation. J. Gen. Virol. 86 3 (2005) 551-559
59. Shinozaki K., Yasui K., and Agematsu K. Direct B/B-cell interactions in immunoglobulin synthesis. Clin. Exp. Immunol. 124 3 (2001) 386-391
60. Spender L.C., Lucchesi W., Bodelon G., Bilancio A., Karstegl C.E., Asano T., Dittrich-Breiholz O., Kracht M., Vanhaesebroeck B., and Farrell P.J. Cell target genes of Epstein-Barr virus transcription factor EBNA-2: Induction of the p55{alpha} regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J. Gen. Virol. 87 10 (2006) 2859-2867
61. Stewart S.E., Dawson C.W., Takada K., Curnow J., Moody C.A., Sixbey J.W., and Young L.S. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-{kappa}B transcription factor pathway. Proc. Natl. Acad. Sci. U. S. A. 101 44 (2004) 15730-15735
62. Subklewe M., Sebelin K., Block A., Meier A., Roukens A., Paludan C., Fonteneau J.-F., Steinman R.M., and Münz C. Dendritic cells expand Epstein-Barr virus-specific CD8+ T cell responses more efficiently than EBV-transformed B cells. Hum. Immunol. 66 9 (2005) 938-949
63. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., and Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102 43 (2005) 15545-15550
64. Sugden B., Phelps M., and Domoradzki J. Epstein-Barr virus DNA is amplified in transformed lymphocytes. J. Virol. 31 3 (1979) 590-595
65. Sugimoto M., Tahara H., Ide T., and Furuichi Y. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res. 64 (2004) 3361-3364
66. Sun C.C., and Thorley-Lawson D.A. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J. Virol. 81 24 (2007) 13566-13577
67. Swanson-Mungerson M., Bultema R., and Longnecker R. Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro. J. Virol. 80 14 (2006) 6764-6770
68. Takahashi T., Kawabe T., Okazaki Y., Itoh C., Noda K., Tajima M., Satoh M., Goto M., Mitsui Y., Tahara H., Ide T., Furuichi Y., and Sugimoto M. In vitro establishment of tumorigenic human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. DNA Cell Biol. 22 11 (2003) 727-735
69. Tarte K., De Vos J., Zhan F., Klein B., and Shaughnessy J.D. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 102 (2003) 592-600
70. Teng G., and Papavasiliou F.N. Shhh! Silencing by microRNA-155. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 364 1517 (2009) 631-637
71. Thal M.A., Carvalho T.L., He T., Kim H.-G., Gao H., Hagman J., and Klug C.A. Ebf1-mediated down-regulation of Id2 and Id3 is essential for specification of the B cell lineage. Proc. Natl. Acad. Sci. U. S. A. 106 2 (2009) 552-557
72. Thorley-Lawson D.A., and Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350 13 (2004) 1328-1337
73. Wang S.E., Wu F.Y., Shin I., Qu S., and Arteaga C.L. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type {kappa} is required for TGF-{beta} function. Mol. Cell. Biol. 25 11 (2005) 4703-4715
74. Wendel-Hansen V., Rosén A., and Klein G. EBV-transformed lymphoblastoid cells down-regulate EBNA in parallel with secretory differentiation. Int. J. Cancer 39 3 (1987) 404-408
75. Wroblewski J.M., Copple A., Batson L.P., Landers C.D., and Yannelli J.R. Cell surface phenotyping and cytokine production of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J. Immunol. Methods 264 1 (2002) 19-28
76. WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J. Biol. Chem. 277 39 (2002) 36329-363377
77. Xu Y., Tan L.-J., Grachtchouk V., Voorhees J.J., and Fisher G.J. Receptor-type protein-tyrosine phosphatase-{kappa} regulates epidermal growth factor receptor. J. Biol. Chem. 280 52 (2005) 42694-42700
78. Xu S., Green M., Kingsley L., Webber S., and Rowe D. A comparison of quantitative-competitive and realtime PCR assays using an identical target sequence to detect Epstein-Barr virus viral load in the peripheral blood. J. Immunol. Methods 137 (2006) 205-212
79. Yin Q., McBride J., Fewell C., Lacey M., Wang X., Lin Z., Cameron J., and Flemington E.K. microRNA-155 is an Epstein-Barr virus-induced gene that modulated Epstein-Barr virus-regulated gene expression pathways. J. Virol. 82 11 (2008) 5295-5306
80. Yoshida H., Matsui T., Yamamoto A., Okada T., and Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107 7 (2001) 881-891
81. Young P., Anderton E., Paschos K., White R., and Allday M.J. Epstein-Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and co-chaperones. J. Gen. Virol. 89 4 (2008) 866-877
82. Yuan J., Cahir-McFarland E., Zhao B., and Kieff E. Virus and cell RNAs expressed during Epstein-Barr virus replication. J. Virol. 80 5 (2006) 2548-2565
83. Zalani S., Holley-Guthrie E., and Kenney S. The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. J. Virol. 69 6 (1995) 3816-3823
84. Zhan F., Huang Y., Colla S., Stewart J.P., Hanamura I., Gupta S., Epstein J., Yaccoby S., Sawyer J., Burington B., Anaissie E., Hollmig K., Pineda-Roman M., Tricot G., van Rhee F., Walker R., Zangari M., Crowley J., Barlogie B., and Shaughnessy J.D. The molecular classification of multiple myeloma. Blood 108 6 (2006) 2020-2028
85. Zhang W., Ratain M.J., and Dolan M.E. The HapMap resource is providing new insights into ourselves and its application to pharmacogenomics. Bioinform. Biol. Insights 2 (2008) 15-23
86. Zhao B., Maruo S., Cooper A., Chase M.R., Johannsen E., Kieff E., and Cahir-McFarland E. RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. Proc. Natl. Acad. Sci. U. S. A. 103 6 (2006) 1900-1905
87. Zhao Y., Yao Y., Xu H., Lambeth L., Smith L.P., Kgosana L., Wang X., and Nair V. A functional microRNA-155 ortholog encoded by the oncogenic Marek's disease virus. J. Virol. 83 1 (2009) 489-492
88. Zhu H., Cong J.-P., Mamtora G., Gingeras T., and Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 95 24 (1998) 14470-14475